Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 6/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TK1 | P04183 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088129 | 0.92 | CYP1A2 (0.60) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL15640688 | 0.90 | TYMS (0.53) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL15640689 | 0.90 | TYMS (0.53) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL1672564 | 0.90 | TYMS (0.48) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL26328051 | 0.89 | TYMS (0.53) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL15640723 | 0.87 | TYMS (0.49) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL15640722 | 0.87 | TYMS (0.49) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL14286636 | 0.87 | TYMS (0.48) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL5064823 | 0.87 | TYMS (0.48) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3510921 | 0.87 | TYMS (0.48) | TYMSCYP1A2CYP3A4TSHRTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2581382-A2 | Radiolabeled compounds and compositions, their precursors and methods for their production | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-04-17 | — | — | EP | disclosed |
| US-8114381-B2 | Radiolabeled compounds and compositions, their precursors and methods for their production | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20080038191-A1 | Radiolabeled Compounds And Compositions, Their Precursors And Methods For Their Production | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038191-A1 | Radiolabeled Compounds And Compositions, Their Precursors And Methods For Their Production | GMNN, MEN1, NCLN | TYMS 1502/4885CYP1A2 4389/4885CYP3A4 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.